17.04.2020 Novavax Daily Analysis

17.04.2020 Novavax Daily Analysis

(NASDAQ: NVAX) 18.10usd,+0.57, +3.25% Novavax (NASDAQ: NVAX) announced yesterday that it has called upon the expertise of Australian based Nucleus Network (Nucleus) to start their  Phase 1 clinical trials for the first confirmed COVID-19 vaccine trial. This announcement triggered the 3.25 percent gains that the company experienced and today it is trading on 18.0usd. This trial is going to be the third confirmed global COVID19 vaccine trial and also the first to be recorded in Australia and it is going to be tested in humans in the coming weeks. Novavax has managed to reach to the level where they can start a trial for Covid -19 vaccine because they made some efforts before on vaccines for two other recent coronavirus epidemics which severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) with their work on Ebola phase 1 trial which was also conducted in Australia.